• Search Funds
  • Model Portfolios
  • Provider
  • Sector
  • Manager

Search by provider name

Search by sector name

Search by manager name

Search by Risk Level

AXA Framlington Biotech Z INC

  • Fund Info & charges
  • Performance
  • Fund breakdown
  • Dividend History
Fund Provider AXA Investment Managers UK Ltd
Fund Summary The aim of this Fund is to provide long-term capital growth.
SEDOL code BRJZVL2
ISIN GB00BRJZVL27
Fund code FMBZI
Managers Linden Thomson, Dani Saurymper
Manager Tenure 7 years
Morningstar Category Sector Equity Biotechnology
IMA Sector Specialist
Fund Size £365 million
Fund Type OEIC
Management Style Active
Total Expense Ratio (TER) 0.82%
Cavendish ongoing charge 0.05%
FundsNetwork Service Fee 0.20%
Minimum Initial Investment £25
Minimum Top Up £25
Minimum Monthly Investment £25
Sell Price £1.1290
Buy Price £1.1290
Price Change -1.3111%
Price Date 15th November 2019
Yield Currently unavailable
Dividend Frequency Semi-Annually
ISA Eligible Yes
SIPP Eligible Yes
Inception Date 2nd March 2015
Fund Status OPEN

3-year Mean Monthly Return: 0.519%

Annual Returns 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009
Fund Performance -17.05% +14.61% +12.36% +11.10% +14.11% +30.88% +47.46% +46.09% +7.52% -5.44%
Benchmark Performance
(Sector Equity Biotechnology)
-13.83% +8.79% +13.25% +12.30% +12.71%
Time Period Cumulative Benchmark Performance
(Sector Equity Biotechnology)
Fund Compared to Benchmark
1 day -1.31% +15.85% -17.16%
1 week -0.53% +8.87% -9.40%
1 month 6.31% -0.97% +7.28%
3 months -4.00% +5.39% -9.38%
6 months -1.31% +8.29% -9.61%
1 year 1.99% +3.33% -1.34%
3 years 2.35% +6.40% -4.05%
5 years 4.97% +16.27% -11.30%
10 years 16.06% +7.38% +8.68%
YTD 10.47% +0.88% +9.59%
Since inception 7.70% Currently unavailable Currently unavailable

Top 10 shares for this fund

Share Name Country Value
Amgen Inc USA 8.71%
Alexion Pharmaceuticals Inc USA 6.62%
Gilead Sciences Inc USA 6.59%
Biogen Inc USA 6.34%
Biomarin Pharmaceutical Inc USA 4.19%
Vertex Pharmaceuticals Inc USA 3.70%
Celgene Corp USA 3.56%
Illumina Inc USA 3.56%
Takeda Pharmaceutical Co Ltd JPN 3.09%
Alnylam Pharmaceuticals Inc USA 2.96%

Currently unavailable